Literature DB >> 29739718

Immunogenicity of a Staphylococcus aureus-cholera toxin A2/B vaccine for bovine mastitis.

N Misra1, T F Wines2, C L Knopp2, R Hermann3, L Bond4, B Mitchell5, M A McGuire6, J K Tinker7.   

Abstract

Staphylococcus aureus causes a chronic, contagious disease of the udder, or mastitis, in dairy cows. This infection is often refractory to antibiotic treatment, and has a significant economic impact on milk production worldwide. An effective vaccine to prevent S. aureus mastitis would improve animal health, reduce antibiotic dependence and inform human vaccine approaches. The iron-regulated surface determinant A (IsdA) and clumping factor A (ClfA) are conserved S. aureus extracellular-matrix adhesins and target vaccine antigens. Here we report the results of two bovine immunogenicity trials using purified IsdA and ClfA-cholera toxin A2/B chimeras (IsdA-CTA2/B and ClfA-CTA2/B). Cows were intranasally inoculated with IsdA-CTA2/B + ClfA-CTA2/B at dry off and followed for 70 days. Trial 1 utilized three groups with one or two booster doses at a total concentration of 600 or 900 μg. Trial 2 utilized two groups with one booster at a total concentration of 1200 μg. Humoral immune responses in serum and milk were examined by ELISA. Responses in serum were significant between groups and provide evidence of antigen-specific IgG induction after vaccination in both trials. Cellular proliferation was detected by flow cytometry using antigen-stimulated PBMCs from day 60 of Trial 2 and revealed an increase in CD4+ T cells from vaccinated cows. IsdA and ClfA stimulation induced IL-4 expression, but not IFN-γ or IL-17, in PBMCs from day 60 as determined by cytokine expression analysis. Opsonophagocytosis of S. aureus confirmed the functional in vitro activity of anti-IsdA antibodies from Trial 2 serum and milk. The vaccine was well tolerated and safe, and results support the potential of mucosally-delivered CTA2/B chimeras to protect cows from mastitis caused by S. aureus.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bovine; Mastitis; Staphylococcus; Vaccine

Mesh:

Substances:

Year:  2018        PMID: 29739718      PMCID: PMC6014625          DOI: 10.1016/j.vaccine.2018.04.067

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  62 in total

1.  Demonstration of intracellular Staphylococcus aureus in bovine mastitis alveolar cells and macrophages isolated from naturally infected cow milk.

Authors:  A Hébert; K Sayasith; S Sénéchal; P Dubreuil; J Lagacé
Journal:  FEMS Microbiol Lett       Date:  2000-12-01       Impact factor: 2.742

2.  Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis.

Authors:  Xin Li; Jarrod L Erbe; C Virginia Lockatell; David E Johnson; Michael G Jobling; Randall K Holmes; Harry L T Mobley
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

3.  Sources of intramammary infections from Staphylococcus aureus in dairy heifers at first parturition.

Authors:  J R Roberson; L K Fox; D D Hancock; J M Gay; T E Besser
Journal:  J Dairy Sci       Date:  1998-03       Impact factor: 4.034

4.  Diversity and antimicrobial susceptibility profiling of staphylococci isolated from bovine mastitis cases and close human contacts.

Authors:  T Schmidt; M M Kock; M M Ehlers
Journal:  J Dairy Sci       Date:  2015-07-15       Impact factor: 4.034

5.  Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits.

Authors:  G Hajishengallis; S K Hollingshead; T Koga; M W Russell
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

Review 6.  Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant.

Authors:  J Holmgren; C Czerkinsky; N Lycke; A M Svennerholm
Journal:  Am J Trop Med Hyg       Date:  1994       Impact factor: 2.345

7.  Comparison of disease severity scoring systems for dairy cattle with acute coliform mastitis.

Authors:  John R Wenz; Franklyn B Garry; George M Barrington
Journal:  J Am Vet Med Assoc       Date:  2006-07-15       Impact factor: 1.936

8.  In vivo and in vitro demonstration that Staphylococcus aureus is an intracellular pathogen in the presence or absence of fibronectin-binding proteins.

Authors:  Eric Brouillette; Gilles Grondin; Lulzim Shkreta; Pierre Lacasse; Brian G Talbot
Journal:  Microb Pathog       Date:  2003-10       Impact factor: 3.738

9.  The three-dimensional crystal structure of cholera toxin.

Authors:  R G Zhang; D L Scott; M L Westbrook; S Nance; B D Spangler; G G Shipley; E M Westbrook
Journal:  J Mol Biol       Date:  1995-08-25       Impact factor: 5.469

10.  T helper 17-associated cytokines are produced during antigen-specific inflammation in the mammary gland.

Authors:  Pascal Rainard; Patricia Cunha; Salim Bougarn; Angélina Fromageau; Christelle Rossignol; Florence B Gilbert; Patricia Berthon
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

View more
  4 in total

1.  Evaluation of the Efficacy of a Cholera-Toxin-Based Staphylococcus aureus Vaccine against Bovine Intramammary Challenge.

Authors:  Hussain A Alabdullah; Elise Overgaard; Danielle Scarbrough; Janet E Williams; Omid Mohammad Mousa; Gary Dunn; Laura Bond; Mark A McGuire; Juliette K Tinker
Journal:  Vaccines (Basel)       Date:  2020-12-24

Review 2.  Progress towards the Elusive Mastitis Vaccines.

Authors:  Pascal Rainard; Florence B Gilbert; Rodrigo P Martins; Pierre Germon; Gilles Foucras
Journal:  Vaccines (Basel)       Date:  2022-02-15

Review 3.  Review on skeletal disorders caused by Staphylococcus spp. in poultry.

Authors:  Gustaw M Szafraniec; Piotr Szeleszczuk; Beata Dolka
Journal:  Vet Q       Date:  2022-12       Impact factor: 3.320

4.  Vaccination with a live-attenuated small-colony variant improves the humoral and cell-mediated responses against Staphylococcus aureus.

Authors:  Julie Côté-Gravel; Eric Brouillette; François Malouin
Journal:  PLoS One       Date:  2019-12-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.